PROSPER Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
'''Click [[ | '''Click [[media:Prosper.pptx|here]] to download slides for PROSPER.''' | ||
==Overview== | ==Overview== | ||
Latest revision as of 15:43, 16 October 2014
|
Low Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
PROSPER Trial On the Web |
|
American Roentgen Ray Society Images of PROSPER Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Click here to download slides for PROSPER.
Overview
Pravastatin 40 mg daily reduced the incidence of non-fatal MI and CHD death during a follow-up of 3.2 years, in this trial involving the 2804 elderly men and 3000 women with a history of, or risk factors for vascular disease. This trial extended the treatment strategies to elderly population[1].
References
- ↑ Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM; et al. (2002). "Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial". Lancet. 360 (9346): 1623–30. PMID 12457784. Review in: ACP J Club. 2003 Jul-Aug;139(1):9